KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Expenses (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Operating Expenses for 7 consecutive years, with $43.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 28.7% year-over-year to $43.9 million, compared with a TTM value of $178.1 million through Dec 2025, down 25.72%, and an annual FY2025 reading of $178.1 million, down 25.72% over the prior year.
  • Operating Expenses was $43.9 million for Q4 2025 at Aurinia Pharmaceuticals, roughly flat from $43.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $74.8 million in Q4 2023 and bottomed at $40.6 million in Q1 2025.
  • Average Operating Expenses over 5 years is $57.9 million, with a median of $58.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 99.89% in 2021, then plummeted 36.09% in 2025.
  • Year by year, Operating Expenses stood at $56.1 million in 2021, then increased by 0.76% to $56.5 million in 2022, then skyrocketed by 32.25% to $74.8 million in 2023, then fell by 17.7% to $61.5 million in 2024, then fell by 28.7% to $43.9 million in 2025.
  • Business Quant data shows Operating Expenses for AUPH at $43.9 million in Q4 2025, $43.7 million in Q3 2025, and $49.9 million in Q2 2025.